PLx Pharma Winddown (PLx Pharma Winddown) Momentum Rank : 0 (As of May. 11, 2024)

View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Winddown Momentum Rank?

PLx Pharma Winddown has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

PLx Pharma Winddown Momentum Rank Related Terms

Thank you for viewing the detailed overview of PLx Pharma Winddown's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

PLx Pharma Winddown (PLx Pharma Winddown) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Winddown Corp (OTCPK:PLXPQ) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 The Green, Suite 11895, Dover, DE, USA, 19901

Website

https://www.plxpharma.com

PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

Executives

Rita M O'connor	officer: Chief Financial Officer	4 OAK PARKWAY, SPARTA NJ 07871
Natasha Giordano	director, officer: Chief Executive Officer	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael J Valentino	director, officer: Executive Chairman	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
John Hadden	director	1375 S FORT HARRISON AVE, CLEARWATER FL 33756
Robert D. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Molly G. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Level One Partners, Llc	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Kirk K Calhoun	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Gary S. Balkema	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Robert Casale	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Anthony Bartsh	director	C/O PARK WEST ASSET MANAGEMENT, LLC, 900 LARKSPUR CIRCLE, SUITE 165, LARKSPUR CA 94939
Park West Asset Management Llc	10 percent owner	1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Efthymios Deliargyris	officer: Chief Medical Officer	C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Gary L Mossman	officer: Chief Operating Officer	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
David Emerson Jorden	officer: Acting Chief Financial Officer	2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381